Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2019 2020

Details for Mechanism ID: 17397
Country/Region: Angola
Year: 2017
Main Partner: Charles R. Drew University of Medicine and Science
Main Partner Program: NA
Organizational Type: University
Funding Agency: USDOD
Total Funding: $782,690 Additional Pipeline Funding: $750,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $183,020
Health Systems Strengthening (OHSS) $0
Testing: HIV Testing and Counseling (HVCT) $84,547
Sexual Prevention: Other Sexual Prevention (HVOP) $215,600
Treatment: Adult Treatment (HTXS) $299,523
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 21,475
HTS_TST Service Delivery Point Agg Age (Community) VCT Mod: 15+, Female, Negative 2018 37
HTS_TST Service Delivery Point Agg Age (Community) VCT Mod: 15+, Male, Negative 2018 7,763
HTS_TST Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative 2018 43
HTS_TST Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative 2018 34
HTS_TST Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative 2018 103
HTS_TST Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative 2018 58
HTS_TST Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Negative 2018 232
HTS_TST Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Negative 2018 345
HTS_TST Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Negative 2018 785
HTS_TST Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Negative 2018 1,153
HTS_TST Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative 2018 372
HTS_TST Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative 2018 961
HTS_TST Service Delivery Point Agg Age (Facility) VCT: <15, Female, Negative 2018 878
HTS_TST Service Delivery Point Agg Age (Facility) VCT: <15, Male, Negative 2018 1,235
HTS_TST Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative 2018 1,556
HTS_TST Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative 2018 4,967
HTS_TST Sum of Test Result disaggregates 2018 953
HTS_TST_POS By Test Result: Positive 2018 953
HTS_TST_POS Service Delivery Point Agg Age (Community) VCT Mod: 15+, Female, Positive 2018 8
HTS_TST_POS Service Delivery Point Agg Age (Community) VCT Mod: 15+, Male, Positive 2018 317
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive 2018 5
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive 2018 3
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive 2018 11
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive 2018 7
HTS_TST_POS Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Positive 2018 11
HTS_TST_POS Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Positive 2018 23
HTS_TST_POS Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Positive 2018 92
HTS_TST_POS Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Positive 2018 47
HTS_TST_POS Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive 2018 27
HTS_TST_POS Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive 2018 73
HTS_TST_POS Service Delivery Point Agg Age (Facility) VCT: <15, Female, Positive 2018 17
HTS_TST_POS Service Delivery Point Agg Age (Facility) VCT: <15, Male, Positive 2018 33
HTS_TST_POS Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive 2018 47
HTS_TST_POS Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive 2018 231
PP_PREV Age/sex: 15-19 Female 2018 309
PP_PREV Age/sex: 15-19 Male 2018 1,087
PP_PREV Age/sex: 20-24 Female 2018 2,175
PP_PREV Age/sex: 20-24 Male 2018 6,419
PP_PREV Age/sex: 25-49 Female 2018 3,416
PP_PREV Age/sex: 25-49 Male 2018 7,740
PP_PREV Age/sex: 50+ Female 2018 23
PP_PREV Age/sex: 50+ Male 2018 407
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 21,576
PP_PREV Sum of Age/Sex disaggregates 2018 21,576
TX_CURR Aggregated Age/Sex: 15+ Female 2018 653
TX_CURR Aggregated Age/Sex: 15+ Male 2018 1,897
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 2,550
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 2,550
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 2,550
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 87
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 653
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 740
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 740
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 1,020
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 714
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 224
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 490
TX_PVLS Numerator: Indication: Targeted 2018 714
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 320
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 700
TX_PVLS_den Denominator: Indication: Targeted 2018 1,020
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 52
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 470
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 522
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 644
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 59
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 585